NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment

Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an announcement.

On April 7, 2025, NeuroSense Therapeutics announced its financial results for the year ending December 31, 2024, and provided business updates. The company reported significant progress in its Phase 2b study of PrimeC for ALS, which showed that the drug slows disease progression and improves survival rates. The study’s success has led to ongoing discussions for advancing PrimeC to a Phase 3 study and eventual commercialization. NeuroSense also plans to file for early commercialization in Canada, with a potential market opportunity of $100 million to $150 million in peak annual revenues. Financially, the company saw a decrease in research and development expenses and general administrative expenses compared to the previous year, with cash reserves of approximately $3.4 million as of the end of 2024.

Spark’s Take on NRSN Stock

According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.

Neurosense Therapeutics Ltd. receives a low overall score due to severe financial challenges, including the lack of revenue and profitability, and a weak balance sheet. While technical analysis suggests a neutral trend, the negative valuation metrics highlight the financial risks. The company’s dependency on external financing without clear revenue streams presents significant uncertainty for investors.

To see Spark’s full report on NRSN stock, click here.

More about Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing novel treatments for severe neurodegenerative diseases. The company is primarily engaged in the development of PrimeC, a therapeutic candidate aimed at treating amyotrophic lateral sclerosis (ALS).

YTD Price Performance: -13.91%

Average Trading Volume: 154,638

Technical Sentiment Signal: Strong Buy

Current Market Cap: $23M

See more data about NRSN stock on TipRanks’ Stock Analysis page.